Method of High-Throughput Drug Screening

The development of effective drugs remains a challenging, risky and expensive endeavor. Currently it takes an estimated 7-10 years to develop and market a drug at a cost that exceeds $800 million. In addition, advances in combinational chemistry are resulting in a large supply of chemical compounds that need to be screened for their efficacy in fighting disease. However, high-throughput drug screening (HTS) is emerging in the field as pharmaceuticals and biotechnology companies compete to become the first to market new drugs. Being able to rapidly screen libraries of compounds reduces the need to prioritize, and provides early lead compounds for evaluation in disease models. Dr. Barrows and colleagues have developed a novel method of liquid-phase, high-throughput drug screening of candidate molecule-protein binding without the use of molecular markers or surface attachment chemistry.

Pharmaceutical and biotechnology companies are racing to identify and test new chemical entities that may be turned into therapeutic drugs. Consequently, demand will rise for high throughput screening (HTS) technologies, which enable researchers to screen large numbers of compounds quickly. The market for novel high-throughput screening products is estimated to reach $225M in 2004 and growth will continue at a moderate compound annual rate of 19% to reach approximately $540M worldwide in 2009.

Stage of Development
The patentability of this technology is under review. This technology is part of an active and ongoing research program and has been demonstrated to work in proof-of-concept experiments. It is available for licensing under either exclusive or non-exclusive terms.

Additional Info

Inventor(s): Cynthia Andjelic, Louis Barrows, Ryan Sincic

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent